U.S. markets close in 4 hours 37 minutes

Cardlytics, Inc. (CDLX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
127.00+2.46 (+1.98%)
As of 11:20AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close124.54
Bid126.05 x 1300
Ask126.63 x 800
Day's Range124.50 - 127.00
52 Week Range39.52 - 161.47
Avg. Volume491,974
Market Cap3.877B
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-2.04
Earnings DateMay 04, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est143.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cardlytics Announces Timing of Its First Quarter 2021 Financial Results Conference Call and Webcast

    Cardlytics Announces Timing of Its First Quarter 2021 Financial Results Conference Call and Webcast

    ATLANTA, April 20, 2021 (GLOBE NEWSWIRE) -- Cardlytics, Inc., (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced that its first quarter ended March 31, 2021 financial results will be released on Tuesday, May 4, 2021, after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company’s financial results. A live audio webcast of the event will be available on the Cardlytics Investor Relations website at http://ir.cardlytics.com/. A live dial-in will be available at (877) 407-3982 (domestic) or (201) 493-6780 (international). The conference ID number is 13719188. Shortly after the conclusion of the call, a replay of this conference call will be available through 8:00 PM ET on May 11, 2021 at (844) 512-2921 (domestic) or (412) 317-6671 (international). The replay passcode is 13719188. About CardlyticsCardlytics (NASDAQ: CDLX) is a digital advertising platform. We partner with financial institutions to run their banking rewards programs that promote customer loyalty and deepen banking relationships. In turn, we have a secure view into where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in London, New York, San Francisco, Austin and Visakhapatnam. In March 2021, Cardlytics acquired Dosh, a transaction-based advertising platform, and has entered into a definitive agreements to acquire Bridg, a customer data platform. Learn more at www.cardlytics.com. Contacts: Public Relations:Angie AmbergCardlytics, Inc.aamberg@cardlytics.com Investor Relations:William MainaICR, Inc.(646) 277-1236ir@cardlytics.com

  • Is CDLX Stock A Buy or Sell?
    Insider Monkey

    Is CDLX Stock A Buy or Sell?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Cardlytics To Snap Up Bridg For $350M; Shares Dip

    Cardlytics To Snap Up Bridg For $350M; Shares Dip

    Cardlytics inked a cash deal to acquire Bridg, a customer data platform, for $350 million. However, shares of the digital advertising platform dropped 6.1% on April 13. This acquisition will combine Cardlytics’ (CDLX) advertising platform, having more than 163 million monthly active users, with Bridg’s advanced SKU-level insights and capability to connect consumers across other digital platforms, the company said. Notably, the cloud-based platform of Bridg is used by retailers and CPG marketers for various applications. Per the terms of the deal, in addition to deal value, based on Bridg’s U.S. annualized revenue run rate, Cardlytics is likely to pay $100 million to $300 million in total at the end of the first and second year, post-acquisition, in cash and stock. Cardlytics CEO Lynne Laube said, “Since founding Cardlytics, our vision was to have a broad view into consumer spend with a detailed understanding of a customer’s individual product preferences. Once we integrate this SKU-level data, we will be able to deliver significant reach, along with targeting and measurement capabilities to brands across all of their marketing investments.” (See Cardlytics stock analysis on TipRanks) Following the deal announcement, Raymond James analyst Aaron Kessler reiterated a Hold rating. Kessler believes “the acquisition brings important SKU level data the Cardlytics platform which CDLX has not had previously (focused on retailer level data)…Overall, we are positive on the acquisition given the SKU level data and further potential to expand its services outside (e.g. measurement).” Overall, the stock has a Hold consensus rating based on 1 Buy and 5 Holds. The average analyst price target of $138.25 implies 31% upside potential from current levels. Shares have increased 25% over the past six months. TipRanks’ Hedge Fund Trading Activity tool shows that confidence in Cardlytics is currently Neutral, as 6 hedge funds decreased their cumulative holdings of the stock by 198,000 shares in the last quarter. Related News: Hologic To Snap Up Mobidiag For $795M, Provide Growth Platform PAR Technology Buys Punchh For $500M; Shares Pop 25.5% Orbcomm To Be Acquired By GI Partners For $1.1B; Shares Pop 52% More recent articles from Smarter Analyst: Public Storage Snaps Up ezStorage For $1.8B Gilead’s Bladder Cancer Drug Trodelvy Gets FDA Nod Procter & Gamble Bumps Up Quarterly Dividend By 10% T. Rowe Price’s March AUM Rise On Higher Equity Assets; Shares Drop